Dendritic cell vaccination
/in Breast Cancer, Colorectal Cancer, Hypernephroma, International Publications, Malignant Melanoma, Prostate CancerSingle administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine
/in Colorectal Cancer, International PublicationsA study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model
/in Colorectal Cancer, International PublicationsA novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model
/in Colorectal Cancer, International PublicationsSuccessful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice
/in Colorectal Cancer, International PublicationsTissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response
/in Colorectal Cancer, International PublicationsTumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ
/in Colorectal Cancer, International PublicationsDendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells
/in Colorectal Cancer, International PublicationsSuperior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma
/in Colorectal Cancer, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer